• +1-646-491-9876
    • +91-20-67278686

    Search

    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016

    • Report Code ID: RW0001492679
    • Category Pharmaceuticals
    • No. of Pages 80
    • Publication Month Oct-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's, 'Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Review, H2 2016', provides in depth analysis on Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted pipeline therapeutics.

    The report provides comprehensive information on the Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics development and features dormant and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

    Note:
    *Certain sections in the report may be removed or altered based on the availability and relevance of data.
    *Updated report will be delivered in 48 hours of order confirmation.

    Report Scope

    - The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
    - The report reviews Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents 2
    List of Tables 5
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) Overview 7
    Therapeutics Development 8
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Stage of Development 8
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Therapy Area 9
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Indication 10
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Pipeline Products Glance 12
    Late Stage Products 12
    Early Stage Products 13
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Companies 14
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Products under Development by Universities/Institutes 18
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Therapeutics Assessment 20
    Assessment by Monotherapy/Combination Products 20
    Assessment by Mechanism of Action 21
    Assessment by Route of Administration 22
    Assessment by Molecule Type 24
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 25
    4SC AG 25
    Chipscreen Biosciences Ltd 26
    Curis, Inc. 27
    GlaxoSmithKline Plc 28
    HitGen LTD 29
    IRBM Science Park SpA 30
    Merck & Co., Inc. 31
    Sigma-Tau S.p.A. 32
    Syndax Pharmaceuticals Inc 33
    TetraLogic Pharmaceuticals 34
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Drug Profiles 35
    4SC-202 - Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    CUDC-907 - Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    Drug to Inhibit HDAC-3 for Oncology - Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    entinostat - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    HG-3001 - Drug Profile 50
    Product Description 50
    Mechanism Of Action 50
    R&D Progress 50
    KDAC-0001 - Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    Largazole - Drug Profile 52
    Product Description 52
    Mechanism Of Action 52
    R&D Progress 52
    N-140 - Drug Profile 53
    Product Description 53
    Mechanism Of Action 53
    R&D Progress 53
    remetinostat - Drug Profile 54
    Product Description 54
    Mechanism Of Action 54
    R&D Progress 54
    Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 56
    Product Description 56
    Mechanism Of Action 56
    R&D Progress 56
    Small Molecule to Inhibit Histone Deacetylases for Oncology - Drug Profile 57
    Product Description 57
    Mechanism Of Action 57
    R&D Progress 57
    Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 58
    Product Description 58
    Mechanism Of Action 58
    R&D Progress 58
    ST-3595 - Drug Profile 59
    Product Description 59
    Mechanism Of Action 59
    R&D Progress 59
    tucidinostat - Drug Profile 60
    Product Description 60
    Mechanism Of Action 60
    R&D Progress 60
    vorinostat - Drug Profile 63
    Product Description 63
    Mechanism Of Action 63
    R&D Progress 63
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Dormant Projects 67
    Histone Deacetylase 3 (SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98) - Featured News & Press Releases 69
    Jun 08, 2016: Curis Announces Oral Presentation of Clinical Data Update from the Phase 1 Study of CUDC-907 at the 21st Congress of the European Hematology Association 69
    Jun 02, 2016: Curis Announces Presentations Related to CUDC-907 at 2016 ASCO Annual Meeting 69
    May 18, 2016: Entinostat Data to be Highlighted at the American Society of Clinical Oncology 2016 Annual Meeting 69
    Apr 11, 2016: Syndax Announces Entinostat Data to be Presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting 70
    Apr 11, 2016: Curis Announces Presentation of Preclinical Data for CUDC-907 at AACR Annual Meeting 71
    Apr 04, 2016: Curis Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology 72
    Mar 21, 2016: Epigenetic compound 4SC-202 strengthens endogenous immune response to cancer 72
    Mar 03, 2016: HUYA Bioscience International Expands Senior Management Team 73
    Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 73
    Dec 06, 2015: Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at the 2015 ASH Annual Meeting 74
    Dec 03, 2015: Syndax Announces Multiple Data Presentations on Entinostat at Upcoming San Antonio Breast Cancer Symposium 75
    Dec 01, 2015: Syndax Announces Initiation Of Entinostat Clinical Program In Japan By Partner Kyowa Hakko Kirin 76
    Nov 05, 2015: Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting 77
    Nov 02, 2015: TetraLogic Announces the Opening of an IND for SHAPE Gel in Alopecia Areata 77
    Sep 30, 2015: 4SC receives funding from the Eurostars programme for further research of its anti-cancer agent 4SC-202 with an epigenetic mode of action 78
    Appendix 79
    Methodology 79
    Coverage 79
    Secondary Research 79
    Primary Research 79
    Expert Panel Validation 79
    Contact Us 79
    Disclaimer 80

    List of Tables

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Indication, H2 2016 10
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Number of Products under Development by Companies, H2 2016 14
    Products under Development by Companies, H2 2016 15
    Products under Development by Companies, H2 2016 (Contd..1) 16
    Products under Development by Companies, H2 2016 (Contd..2) 17
    Number of Products under Investigation by Universities/Institutes, H2 2016 18
    Products under Investigation by Universities/Institutes, H2 2016 19
    Assessment by Monotherapy/Combination Products, H2 2016 20
    Number of Products by Stage and Mechanism of Action, H2 2016 21
    Number of Products by Stage and Route of Administration, H2 2016 23
    Number of Products by Stage and Molecule Type, H2 2016 24
    Pipeline by 4SC AG, H2 2016 25
    Pipeline by Chipscreen Biosciences Ltd, H2 2016 26
    Pipeline by Curis, Inc., H2 2016 27
    Pipeline by GlaxoSmithKline Plc, H2 2016 28
    Pipeline by HitGen LTD, H2 2016 29
    Pipeline by IRBM Science Park SpA, H2 2016 30
    Pipeline by Merck & Co., Inc., H2 2016 31
    Pipeline by Sigma-Tau S.p.A., H2 2016 32
    Pipeline by Syndax Pharmaceuticals Inc, H2 2016 33
    Pipeline by TetraLogic Pharmaceuticals, H2 2016 34
    Dormant Projects, H2 2016 67
    Dormant Projects (Contd..1), H2 2016 68

    List of Figures

    Number of Products under Development for, H2 2016 8
    Number of Products under Development by Therapy Area, H2 2016 9
    Number of Products under Development by Top 10 Indication, H2 2016 10
    Comparative Analysis by Late Stage Development, H2 2016 12
    Comparative Analysis by Early Stage Products, H2 2016 13
    Assessment by Monotherapy/Combination Products, H2 2016 20
    Number of Products by Stage and Mechanism of Actions, H2 2016 21
    Number of Products by Routes of Administration, H2 2016 22
    Number of Products by Stage and Routes of Administration, H2 2016 22
    Number of Products by Stage and Molecule Type, H2 2016 24
    4SC AG
    Chipscreen Biosciences Ltd
    Curis, Inc.
    GlaxoSmithKline Plc
    HitGen LTD
    IRBM Science Park SpA
    Merck & Co., Inc.
    Sigma-Tau S.p.A.
    Syndax Pharmaceuticals Inc
    TetraLogic Pharmaceuticals

    Request for Sample

    Report Url http://www.reportsweb.com//histone-deacetylase-3-smap45-or-rpd3-2-or-hdac3-or-ec-3-5-1-98-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//histone-deacetylase-3-smap45-or-rpd3-2-or-hdac3-or-ec-3-5-1-98-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//histone-deacetylase-3-smap45-or-rpd3-2-or-hdac3-or-ec-3-5-1-98-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments